Treatments to prevent cluster headaches

Preventive treatments reduce how many attacks you have, or end a cluster cycle altogether. Unlike abortive treatments, they don't stop individual attacks. You usually take them daily (or, for monthly injections, monthly), and the effect builds over days to weeks.

Most cluster headache patients need both a preventive and an abortive. If you rely on abortives alone, you're stuck reacting to every attack rather than reducing how many you get. If you rely on a preventive alone, you have no fast option when an attack breaks through. The two work together.

The right preventive depends on whether you have episodic cluster headache (cycles of weeks to months, with long remission periods) or chronic cluster headache (continuous attacks throughout the year, with little or no remission). Some treatments work well for both, others only for one. The sections below note which is which.

If you have episodic cluster headache and can sense a cycle approaching, starting your preventive a few days before the cycle begins can sometimes stop it from getting going at all. This matters most for fast-acting preventives like psilocybin and LSD; verapamil titrates slowly and is usually started at cycle onset alongside a bridge.

Each treatment section below follows the same structure: a brief description, then Protocol (how to use it), Evidence (what the data show), and Side effects and monitoring (what to watch for).

---

Summary of preventive treatments for cluster headaches

Treatment	Typical dose	Time to effect	Response	Guideline status
Verapamil	360-960 mg/day	1-5 weeks	94% episodic / 56% chronic attack-free at high doses	First-line, episodic and chronic
Galcanezumab (Emgality)	300 mg/month	1-3 weeks	71% with ≥50% reduction at 3 weeks	FDA-approved (US, episodic only); off-label in EU/UK
Lithium	600-1,200 mg/day	~1 week	~50% sustained in chronic; no benefit in episodic RCT	Second-line, particularly chronic
Vitamin D3 ("Batch" protocol)	10,000 IU/day + supporting nutrients	Weeks	80% any benefit (uncontrolled survey)	Not in guidelines; widely used
Psilocybin	~1-1.5 g every 5 days	Days	~50% reduction (RCT); ~75% in surveys	Not in guidelines; widely used
LSD	25-50 µg every 5 days	Days	High in surveys (no RCT)	Not in guidelines
5-MeO-DALT	10-20 mg every 5 days	Days	61-87% in one small survey	Not in guidelines
Melatonin	10 mg at night	3-5 days	~50% in episodic; no effect in chronic	Add-on, especially nocturnal episodic
gammaCore (preventive use)	3 × 2-min stims, twice daily	Weeks	~40% reduction (PREVA, chronic CH)	Weak recommendation, chronic CH
Occipital nerve stimulation (ONS)	Implanted device	2-10 months	~50% with ≥50% reduction	Refractory chronic CH only (specialist)
Deep brain stimulation (DBS)	Implanted electrode	Weeks to months	~70% mean reduction in meta-analysis	Last resort (specialist)

---

Verapamil

Verapamil is the first-line preventive in every major guideline.^[1][2] It's a so-called calcium channel blocker, and it was originally developed as a heart medication, but it has been used for cluster headache since the 1980s. It works for both episodic and chronic cluster headache.

Protocol

You start low and increase slowly. A common schedule is 80 mg three times a day (240 mg per day) to begin with, then increases of 80 mg every one to two weeks. Most people end up between 360 and 720 mg per day. The maximum is usually 960 mg per day, though a small number of patients need 1,200 mg.

These doses are much higher than what's used for heart conditions. A common mistake is for doctors to prescribe migraine-level doses (120 to 240 mg) and conclude the drug doesn't work. If you're not improving, the most likely reason is that the dose is too low.

Evidence

Open-label data at high doses (360–920 mg/day) show that 94% of episodic patients and 56% of chronic patients become attack-free.^[3] The effect builds over one to three weeks for episodic cluster headache and up to five weeks for chronic.

Side effects and monitoring

The most important thing to know about verapamil is that it affects the heart, which is why titration is slow and monitoring is non-negotiable.

• Cardiac effects (the one to watch closely). Verapamil can slow your heart rate and cause first-degree heart block (a delay in the electrical signal between the upper and lower chambers of the heart). In rare cases, the block progresses to the point of needing a pacemaker.^[4] You need an ECG (a tracing of your heart's electrical activity) before starting, and another ECG before each dose increase.^[5] If your doctor isn't ordering ECGs, ask for them. Skipping the monitoring is not safe at these doses.
• Common but manageable. Constipation is the side effect most patients notice first, and it can be significant at higher doses. Fiber, fluids, and a stool softener usually help, and many patients add a daily magnesium supplement (around 400 mg), which also has its own modest preventive reputation in the cluster community. Swollen ankles, fatigue, and dizziness are also common, especially in the first few weeks.
• Less common. Gum overgrowth (gingival hyperplasia) can develop with long-term use; good dental hygiene reduces the risk.

---

Galcanezumab (Emgality)

Galcanezumab (sold as Emgality) is a monthly injection. It's a monoclonal antibody against CGRP, a signaling molecule involved in headache. It's the only drug specifically approved by the FDA for cluster headache, and only for episodic patients.

Protocol

The dose is 300 mg per month, given as three separate injections of 100 mg. That's three times the migraine dose, which is a common source of prescribing errors. You start at the beginning of a cluster cycle and continue monthly until the cycle ends.

Evidence

In the pivotal trial, 71% of patients had at least a 50% reduction in attacks at three weeks, compared to 53% on placebo.^[6] The effect is detectable across the first three weeks.

If you have chronic cluster headache, galcanezumab probably won't help: the chronic trial was negative.^[7] Some real-world reports describe a response in chronic patients, but it shouldn't be the first thing you try.

Side effects and monitoring

Side effects are mild and almost entirely limited to the injection site (redness, itching, mild pain).

The bigger hurdle is access. Galcanezumab is FDA-approved for cluster headache only in the United States. In the EU and UK it's approved for migraine prevention but not for cluster headache, so a cluster headache prescription there is off-label and rarely reimbursed. It's expensive, and US insurance approval can be slow. If you're commercially insured in the US, Lilly's Emgality savings program brings the cost down to as little as $35 per month, for up to 12 months per year. The program is not available to patients on Medicare, Medicaid, or other government-funded plans.

---

Lithium

Lithium has been used for cluster headache since the 1970s. It's a second-line preventive, particularly for chronic cluster headache.

Protocol

You typically start at 300 mg twice a day and titrate up weekly, aiming for a daily total of 600 to 1,200 mg (still split into two doses) with a target blood level of 0.6 to 1.0 mmol/L. Effects often appear within a week.

How long you stay on it depends on which form of cluster headache you have:

• Chronic cluster headache. Lithium is usually taken indefinitely. Long-term case series describe patients remaining on it for months or years with sustained benefit.^[8][9] Attacks tend to return quickly (often within 36 hours) once it's stopped,^[10] so most patients continue as long as the drug is well-tolerated and blood tests stay normal.
• Episodic cluster headache. Take it through the cluster cycle and taper off once you've been attack-free for two to three weeks, the same pattern used for verapamil. Restart at the next cycle.

Evidence

In early studies that followed chronic cluster headache patients on lithium over time, about half had a sustained response and another quarter improved partially.^[9] The one placebo-controlled trial in episodic cluster headache found no benefit over placebo,^[11] so lithium is mainly prescribed for chronic cluster headache. It's rarely a first choice because the safe dose and the toxic dose are close together, and that means regular blood tests.

Side effects and monitoring

• Toxicity. The safe dose and the toxic dose are close together. Blood levels above 1.5 mmol/L cause confusion, tremor, and seizures. You need regular blood tests (lithium level, kidney function, thyroid function): monthly for the first three months, then every three to six months.
• Long-term effects. Lithium can affect the thyroid and the kidneys over years of use. Side effects include tremor, increased thirst and urination, weight gain, and cognitive dulling.
• Drug interactions. Lithium interacts with NSAIDs, ACE inhibitors, and diuretics. Lithium cannot be combined with psychedelics: the combination can cause seizures. If you're on lithium and considering psychedelic treatment, you'd need to come off lithium first, under medical supervision.

---

Vitamin D3 anti-inflammatory regimen

A community-developed regimen, often called the "Batch protocol" after Pete Batcheller, the patient who developed it. The idea is that many cluster headache patients have low vitamin D, and raising it (along with a set of supporting nutrients) reduces attack frequency. The proposed mechanism is that vitamin D lowers inflammation in the body, which may quiet the brain pathways that trigger cluster attacks, but it remains unproven.

Protocol

The protocol starts with a loading phase of high-dose vitamin D3 (around 50,000 IU per day for about a week, then tapering down), followed by a maintenance dose of 10,000 IU per day. Several supporting nutrients are taken alongside daily:

• Omega-3 fish oil: 2,000 to 2,400 mg
• Magnesium: around 400 mg
• Vitamin K2: around 120 µg
• Calcium: around 500 mg
• Plus smaller amounts of vitamin A, zinc, and boron.

The target is to raise your blood vitamin D level (measured as 25-hydroxyvitamin D) to 80 to 100 ng/mL (200 to 250 nmol/L), well above the standard "normal" range. The full protocol is documented at vitamindregimen.com.

Evidence

In a self-reported survey of 110 cluster headache sufferers, 80% reported significant reductions in attack frequency, severity, and duration.^[12]

Side effects and monitoring

10,000 IU per day long-term can cause high blood calcium if not monitored. You need periodic blood tests for vitamin D level and serum calcium. The supporting nutrients have their own toxicity ceilings, particularly boron and vitamin A. Talk to your doctor before starting, especially if you have kidney disease or sarcoidosis.

---

Psilocybin

Psilocybin is the active compound in psychedelic mushrooms. For decades, patients have reported that a small dose every few days can stop a cluster cycle altogether, often after only one to three doses. See our psychedelics guide for the full protocol, evidence, and safety.

Protocol

The community protocol is well-established: take a small dose (around 1 to 1.5 grams of dried mushrooms, sometimes less) on a calm day, wait about five days, then take another. Continue every five days until the cycle breaks, usually after three to five doses. If you can predict when your cycle is coming, starting a few days before its expected onset can prevent the cycle from getting going at all. Many patients also take a single "booster" dose every one to three months as maintenance.

The dose used for cluster headache produces mild psychedelic effects (sharper colors, mild body sensations, a few hours of altered perception). It's not a full trip. Some patients use even smaller doses, so low that no psychedelic effects are felt at all, and still report benefit. However, some patients report needing higher doses. Trial and error must be done with caution.

Before your first dose: clear interfering medications. Several common cluster medications block this protocol or are dangerous to combine with it. Plan ahead with the doctor who prescribed them — never stop a prescription medication abruptly.

• Triptans and ergots must be stopped at least five days before your first dose (seven days for frovatriptan). If you keep taking them, the protocol typically won't work.
• SSRIs, SNRIs, and tricyclic antidepressants also block the protocol and need a much longer taper, often weeks, under medical supervision. Some, like fluoxetine (Prozac), take five to six weeks to clear the body.
• Lithium and MAOIs are categorical contraindications. Lithium combined with psilocybin can cause seizures; MAOIs can cause serotonin syndrome. You'd need to come off these entirely (with your doctor) before considering the protocol at all.

Evidence

Survey data pool more than 5,000 patients across multiple countries, with consistent reports of around 75% efficacy — the highest of any preventive treatment.^[13] A randomized trial extension found psilocybin reduced attack frequency by about 50%.^[14] A Danish trial in chronic patients showed a 31% reduction.^[15]

Side effects and monitoring

At the doses used for cluster headache, the experience is short (four to six hours) and side effects are usually limited to mild anxiety, nausea, or fatigue the next day. Psilocybin is illegal in most countries, though enforcement varies.

---

LSD

LSD works similarly to psilocybin and is reported by some patients to work even better. It acts on the same brain receptors and follows the same five-day dosing protocol. See our psychedelics guide for the LSD-specific protocol and safety.

Protocol

The dose used for cluster headache is small — typically 25 to 50 micrograms (a quarter to half of a recreational dose). At this level, the experience is milder and shorter than a full trip, though LSD lasts longer than psilocybin (up to 8 to 12 hours).

Before your first dose: the same medication-clearing rules as psilocybin apply. Triptans and ergots must be stopped at least five days in advance; SSRIs, SNRIs, and tricyclic antidepressants must be tapered off in advance under medical supervision (often weeks); lithium and MAOIs cannot be combined at all with LSD.

Evidence

In the Sewell 2006 Harvard survey, seven of eight LSD users said it ended their cluster cycle, and four of five said it extended their pain-free remission.^[16] Patient surveys in Europe and the US have found similar effect sizes.^[17]

Side effects and monitoring

LSD is illegal in most countries and harder to source reliably than psilocybin.

---

5-MeO-DALT

5-MeO-DALT (or "DALT") is a lesser-known compound from the same chemical family as psilocybin and DMT. Patients have been using it for cluster headache since around 2015. At the doses used for prevention, it produces almost no hallucinogenic effects, just a mild body feeling for a couple of hours. See our psychedelics guide for the DALT-specific protocol and safety.

Protocol

Typical doses are 10 to 20 mg, taken on a similar schedule to psilocybin (every few days for several doses).

Before your first dose: the same medication-clearing rules as psilocybin apply. Triptans and ergots must be stopped at least five days in advance; SSRIs, SNRIs, and tricyclic antidepressants must be tapered off in advance under medical supervision (often weeks); lithium and MAOIs cannot be combined at all with DALT.

Evidence

The evidence is thin: a 2014 case study of two refractory chronic patients, and a 2015 patient survey of 46 diagnosed cluster headache patients.^[18] In the survey, 87% reported a reduction in attacks; 61% had a dramatic decrease or complete elimination; 46% reported zero attacks after treatment.

Side effects and monitoring

Side effects at these doses are typically mild (light nausea or body warmth). 5-MeO-DALT is still legal in many countries, which makes it accessible where psilocybin and LSD aren't.

---

Melatonin

Melatonin is the hormone your body produces at night to regulate sleep. Cluster headache patients tend to have reduced and shifted melatonin secretion, which is one reason attacks often happen at the same time each night.

Protocol

The studied dose is 10 mg at bedtime, taken about one to two hours before sleep. Some patients in the community use higher doses (15 to 25 mg), reported as helpful when 10 mg isn't enough.

Evidence

In a small randomized trial, half of episodic patients became attack-free within three to five days, compared to none on placebo.^[19] Chronic patients didn't respond. Melatonin isn't a standalone cluster headache treatment in any official guideline, but it's a cheap, safe add-on that's especially worth trying if your attacks are nocturnal and you have episodic cluster headache.

Side effects and monitoring

Side effects are minimal: mild drowsiness and vivid dreams. No specific monitoring is needed.

---

Neuromodulation for refractory cluster headache

For patients whose attacks don't respond to drugs, electrical stimulation of specific nerves or brain regions can reduce how often attacks happen. These approaches sit at the edge of cluster headache care: most are reserved for medically intractable chronic cluster headache, they are available only at specialist headache or pain centers, and most require surgery to implant a device.

The options below are listed from least to most invasive. Only the first is something you can use at home; the others involve surgery and ongoing follow-up.

Non-invasive vagus nerve stimulation (gammaCore) as preventive

gammaCore is the same handheld device used to abort attacks (see the abortive chapter), used here on a fixed daily schedule rather than during an attack. The typical schedule is three 2-minute stimulations on each side of the neck, twice a day — once within an hour of waking, once seven to ten hours later. The PREVA trial in chronic cluster headache showed that gammaCore added to standard care reduced attack frequency more than standard care alone, though the effect was modest and waned after the first month.^[20] EAN 2023 gives a weak recommendation for preventive use in chronic cluster headache. Side effects and access barriers are the same as for abortive use.

Occipital nerve stimulation (ONS)

Occipital nerve stimulation is a surgery in which thin electrodes are placed under the skin at the base of the skull, just over the greater occipital nerves (the same nerves targeted by a GON block), and connected to a small implanted pulse generator placed under the skin of the buttock or abdomen. The device sends a continuous mild electrical pulse to the nerves, dampening the pain pathways that drive cluster attacks. It is the best-studied invasive neuromodulation option for refractory chronic cluster headache.

The procedure is done under general anesthesia in a single surgery, usually with an overnight hospital stay. A response develops gradually over two to ten months, so it is not a fast preventive. Multiple open-label series and the ICON phase 3 randomized trial (138 patients) report that about half of patients have at least a 50% reduction in attack frequency, sustained over years of follow-up.^[21][22][23] EAN 2023 recommends ONS for medically intractable chronic cluster headache after pharmacological options have failed.

The most common problems are hardware-related: lead migration (the electrode shifting), battery depletion, infection at the implant site, and skin irritation. Newer leads with silicone tines have reduced migration rates. Because the response takes months to develop, ONS is offered only after other preventives have clearly failed, and access depends on having a specialist center nearby.

Deep brain stimulation (DBS)

Deep brain stimulation targets the hypothalamus, a small structure deep in the brain that imaging studies show is active during cluster headache attacks. A thin electrode is placed in the posterior hypothalamic region through a small hole in the skull, then connected to a pulse generator implanted under the skin near the collarbone. As with ONS, the effect develops over weeks to months. DBS is reserved for cluster headache only when ONS and SPG-targeted treatments have failed.

Two 2023 meta-analyses of open-label studies in medically intractable chronic cluster headache reported a roughly 70% reduction in average attack frequency^[24] and a pooled responder rate of about 77%.^[25] The one small randomized trial was negative at three months, but six of eleven patients responded in the open-label extension.^[26] EAN 2023 lists DBS as an option of last resort. Complications, although rare, can be serious: intracranial hemorrhage, infection, and oculomotor or sensory changes have all been reported.

Other neuromodulation approaches

Several other approaches have been studied but are either no longer available, only available at a few specialist centers, or supported by very limited evidence.

• Sphenopalatine ganglion stimulation (Pulsante). A small implanted stimulator behind the upper jaw, activated with a handheld remote at the onset of each attack. A sham-controlled trial showed clear benefit for individual attacks in chronic cluster headache,^[27] and longer-term follow-up confirmed durable response in about two-thirds of patients.^[28] The device is no longer commercially available for new implants, but a subset of patients implanted before withdrawal continue to use it.
• Gamma Knife radiosurgery. A non-invasive procedure that delivers focused radiation to the trigeminal nerve root. Results have been mixed, with significant rates of facial numbness and a tendency for benefit to wane over time. Not currently recommended outside research settings.^[29]
• Spinal cord stimulation at the high cervical level. A small number of retrospective reports describe benefit in refractory cluster headache, with the rationale that high cervical stimulation may reach the trigeminocervical complex more effectively than ONS. Evidence is limited; not currently in guidelines.
• Percutaneous pulsed radiofrequency at C1–C2. A needle-based, non-surgical procedure that delivers short bursts of high-frequency current to the upper cervical nerve roots. Reported as modestly helpful in small retrospective series for chronic cluster headache. Like SPG pulsed radiofrequency (see bridge chapter), it is only available at specialist pain centers.

---

Other preventives mentioned in older sources

A few drugs that appear in older guidelines are no longer recommended, or only listed as alternatives when first-line options have failed:

• Methysergide. Once a mainstay; withdrawn in most countries due to risk of retroperitoneal and cardiac fibrosis (scarring around organs).
• Topiramate. An anticonvulsant sometimes tried as a third-line preventive. Open-label evidence is mixed and no randomized trial exists.^[30][31] The most common reason patients stop is cognitive slowing (memory, word-finding, concentration). It can also cause birth defects, so it shouldn't be used in pregnancy.
• Valproate (sodium valproate or valproate semisodium). Positive open-label data in the 1980s, but a later randomized trial showed no benefit over placebo. Side effects are significant (weight gain, hair loss, tremor, liver damage, low platelet count), and it causes birth defects, so it shouldn't be used by anyone who could become pregnant.
• Fremanezumab and erenumab (other CGRP antibodies). Trials in cluster headache were negative. Some specialists try them off-label, but trial evidence doesn't support it.
• OnabotulinumtoxinA (Botox). Tried in two ways. The PREEMPT protocol, the same set of head and neck injections used for chronic migraine, has shown modest reductions in attack frequency in small open-label studies of chronic cluster headache and no clear benefit in episodic. A more targeted approach, injecting Botox directly toward the sphenopalatine ganglion through the nose or cheek, has shown stronger signals in two small studies of refractory chronic cluster headache, and a placebo-controlled trial is ongoing. Both uses are off-label.
• Gabapentin. An anticonvulsant occasionally tried as an add-on when first-line preventives fail. Open-label series in both episodic and chronic patients report some benefit at daily doses of 900 to 3,600 mg, but no randomized trial exists. Common side effects are sleepiness, dizziness, and weight gain.
• Pizotifen, baclofen, intranasal capsaicin/civamide. Used historically, very weak evidence, not in current guideline first-line recommendations.

---

References

1. ↩ May A, Evers S, Goadsby PJ, Leone M, Manzoni GC, Pascual J, et al. (2023). European Academy of Neurology guidelines on the treatment of cluster headache. European Journal of Neurology, 30(10), 2955–2979. doi:10.1111/ene.15956
2. ↩ Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ (2016). Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache, 56(7), 1093–1106. doi:10.1111/head.12866
3. ↩ Petersen AS, Lund N, Goadsby PJ, et al. (2024). Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache. Lancet Neurology, 23(7), 712–724. Link
4. ↩ Cohen AS, Matharu MS, Goadsby PJ (2007). Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. Neurology, 69(7), 668–675. Link
5. ↩ Koppen H, Stolwijk J, Wilms EB, van Driel V, Ferrari MD, Haan J (2016). Cardiac monitoring of high-dose verapamil in cluster headache: an international Delphi study. Cephalalgia, 36(14), 1385–1388. Link
6. ↩ Goadsby PJ, Dodick DW, Leone M, et al. (2019). Trial of galcanezumab in prevention of episodic cluster headache. New England Journal of Medicine, 381(2), 132–141. Link
7. ↩ Dodick DW, Goadsby PJ, Lucas C, et al. (2020). Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia, 40(9), 935–948. Link
8. ↩ Ekbom K (1981). Lithium for cluster headache: review of the literature and preliminary results of long-term treatment. Headache, 21(4), 132–139. Link
9. ↩ Manzoni GC, Bono G, Lanfranchi M, Micieli G, Terzano MG, Nappi G (1983). Lithium carbonate in cluster headache: assessment of its short- and long-term therapeutic efficacy. Cephalalgia, 3(2), 109–114. Link
10. ↩ Bussone G, Boiardi A, Merati B, Crenna P, Picco A (1979). Chronic cluster headache: response to lithium treatment. Journal of Neurology, 221(3), 181–185. Link
11. ↩ Steiner TJ, Hering R, Couturier EG, Davies PT, Whitmarsh TE (1997). Double-blind placebo-controlled trial of lithium in episodic cluster headache. Cephalalgia, 17(6), 673–675. Link
12. ↩ Batcheller P (2014). Survey of cluster headache sufferers using vitamin D3. Neurology, 82(10 Supplement), P1.256. Link
13. ↩ Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M (2022). Self-reported efficacy of treatments in cluster headache: a systematic review of survey studies. Current Pain and Headache Reports, 26(8), 623–637. Link
14. ↩ Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, et al. (2024). Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal of the Neurological Sciences, 460, 122993. doi:10.1016/j.jns.2024.122993
15. ↩ Madsen MK, Petersen AS, Stenbæk DS, et al. (2024). CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache, 64(1), 55–67. doi:10.1111/head.14656
16. ↩ Sewell RA, Halpern JH, Pope HG Jr (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920–1922. doi:10.1212/01.wnl.0000219761.05466.43
17. ↩ Schindler EAD, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA (2015). Indoleamine hallucinogens in cluster headache: Results of the Clusterbusters Medication Use Survey. Journal of Psychoactive Drugs, 47(5), 372–381. doi:10.1080/02791072.2015.1107664
18. ↩ Post M (2015). Cluster headache patient survey: 5-MeO-DALT. Self-published.
19. ↩ Leone M, D'Amico D, Moschiano F, Fraschini F, Bussone G (1996). Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia, 16(7), 494–496. Link
20. ↩ Gaul C, Diener HC, Silver N, et al. (2016). Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia, 36(6), 534–546. Link
21. ↩ Wilbrink LA, de Coo IF, Doesborg PGG, et al. (2021). Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurology, 20(7), 515–525. Link
22. ↩ Burns B, Watkins L, Goadsby PJ (2007). Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. Lancet, 369(9567), 1099–1106. Link
23. ↩ Magis D, Allena M, Bolla M, De Pasqua V, Remacle JM, Schoenen J (2007). Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurology, 6(4), 314–321. Link
24. ↩ Murray M, Pahapill PA, Awad AJ (2023). Deep brain stimulation for chronic cluster headaches: a systematic review and meta-analysis. Stereotactic and Functional Neurosurgery, 101, 232–243. Link
25. ↩ Membrilla JA, Roa J, Díaz-de-Terán J (2023). Preventive treatment of refractory chronic cluster headache: systematic review and meta-analysis. Journal of Neurology, 270, 689–710. Link
26. ↩ Fontaine D, Lazorthes Y, Mertens P, et al. (2010). Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. Journal of Headache and Pain, 11(1), 23–31. Link
27. ↩ Schoenen J, Jensen RH, Lantéri-Minet M, et al. (2013). Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia, 33(10), 816–830. Link
28. ↩ Jürgens TP, Barloese M, May A, et al. (2017). Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia, 37(5), 423–434. Link
29. ↩ Franzini A, Clerici E, Navarria P, Picozzi P (2022). Gamma Knife radiosurgery for the treatment of cluster headache: a systematic review. Neurosurgical Review, 45(3), 1923–1931. Link
30. ↩ Leone M, Dodick D, Rigamonti A, et al. (2003). Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia, 23(10), 1001–1002. Link
31. ↩ Láinez MJA, Pascual J, Pascual AM, Santonja JM, Ponz A, Salvador A (2003). Topiramate in the prophylactic treatment of cluster headache. Headache, 43(7), 784–790. Link